Acumen Pharmaceuticals (ABOS) Change in Accured Expenses (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Change in Accured Expenses data on file, last reported at -$5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 8505.0% year-over-year to -$5.0 million; the trailing twelve-month figure through Mar 2026 stood at -$1.8 million (down 149.71% YoY), and the FY2025 full-year result was $3.3 million, up 10215.62% from the prior year.
• Change in Accured Expenses slipped to -$5.0 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.9 million in Q2 2025 to a low of -$5.0 million in Q1 2026.
• A 5-year average of $35705.9 and a median of $370000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 6266.67% in 2022 and sank 8505.0% in 2026, its largest moves.
• Tracing ABOS's Change in Accured Expenses over 5 years: stood at $500000.0 in 2022, then surged by 512.2% to $3.1 million in 2023, then tumbled by 50.18% to $1.5 million in 2024, then surged by 46.56% to $2.2 million in 2025, then tumbled by 325.64% to -$5.0 million in 2026.
• Business Quant data shows ABOS's Change in Accured Expenses at -$5.0 million in Q1 2026, $2.2 million in Q4 2025, and -$3.9 million in Q3 2025.